^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PMC-309

i
Other names: PMC-309, PMC-309a-z
Associations
Company:
PharmAbcine
Drug class:
VISTA antagonist
Associations
1year
KEYNOTE-E80: Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (clinicaltrials.gov)
P1, N=67, Not yet recruiting, PharmAbcine | Phase classification: P1a/1b --> P1
Phase classification • Metastases
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • PMC-309
1year
KEYNOTE-E80: Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (clinicaltrials.gov)
P1a/1b, N=67, Not yet recruiting, PharmAbcine | Initiation date: Aug 2023 --> Nov 2023
Trial initiation date • Metastases
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • PMC-309
over1year
New P1 trial • Metastases
|
CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • PMC-309